{"schema_version":"secwatch.filing_event.v1","accession":"0001553350-22-000853","form_type":"8-K","ticker":"PDEX","cik":"0000788920","company_name":"PRO DEX INC","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.569935+00:00","generated_at":"2026-06-22T10:31:24.921307+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pro-Dex Q1 revenue up 11% to $11.1M; EPS flat at $0.29; gross margin drops 7 pts","bullets":["Net sales $11.1M (+11% YoY); net income $1.1M ($0.29 diluted EPS) vs $1.1M ($0.28) prior year.","Gross margin fell to 27% from 34% due to costly handpiece upgrades for largest customer; compensation negotiations ongoing.","FDA authorized commencement of manufacturing activities at Franklin facility.","Operating expenses decreased $104K on lower stock compensation and R&D.","CEO confident negotiations with largest customer will lead to additional revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001553350-22-000853","json":"https://secwatch.observer/filing/0001553350-22-000853.json","markdown":"https://secwatch.observer/filing/0001553350-22-000853.md","text":"https://secwatch.observer/filing/0001553350-22-000853.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/788920/000155335022000853/0001553350-22-000853-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/788920/000155335022000853/pdex_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T10:31:24.921307+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6ff9c4d46395deb0308d9e3a14b47af0dfacacb4","claim":"PRO DEX INC reported fiscal 2023 first quarter ended September 30, 2022 results: revenue $11.1 million, net income $1.1 million, EPS $0.29 per diluted share.","evidence_excerpt":"first quarter of fiscal year 2023 with the Securities and Exchange Commission today. Net sales for the three months ended September 30, 2022 increased $1.1 million, or 11%, to $11.1 million from $10.0 million for the three months ended September 30, 2021. The increase is driven primarily by $0.8 million in increased repairs of the surgical handpiece we sell to our","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/788920/000155335022000853/0001553350-22-000853-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal 2023 first quarter ended September 30, 2022"},{"label":"Revenue","value":"$11.1 million"},{"label":"Net income","value":"$1.1 million"},{"label":"EPS","value":"$0.29 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}